肺癌中粘附分子CD44和癌基因cyclinD1的表达

目的探讨肺癌中粘附子分子ＣＤ４４和癌基因ｃｙｃｌｉｎＤ１的表达意义。方法应用Ｓ－Ｐ免疫组织化学方法研究６２例肺癌组织中ＣＤ４４和ｃｙｃｌｉｎＤ１的表达情况。结果６２例肺癌组织中ＣＤ４４和ｃｙｃｌｉｎＤ１的阳性率分别为７１．０％和５０．０％。腺癌和鳞癌的ＣＤ４４的阳性率明显高于小细胞癌（Ｐ〈０．０５）;淋巴结转移阳性组ＣＤ４４的表达显著高于阴性组（Ｐ〈０．０１,γ＝０．５４）。不同组织类型肺癌中ｃｙ     

p16和cyclinD_1蛋白在膀胱移行细胞癌中的表达及意义

 目的探讨ｐ１６、ｃｙｃｌｉｎＤ１蛋白表达与膀胱移行细胞癌（ＴＣＣ）临床分期、病理分级及预后的关系。方法采用免疫组化Ｓ－Ｐ法检测 ５９例膀胱ＴＣＣ中ｐ１６、ｃｙｃｌｉｎＤ１蛋白的表达。结果膀胱ＴＣＣ 组织中 ｐ１６蛋白阳性表达率为 ４２．４％，随临床分期、病理分级增高而下降，ｃｙｃｌｉｎＤ１蛋白阳性表达率为 ６１％，随临床分期增高而上升；ｐ１６、ｃｙｃｌｉｎＤ１蛋白表达间呈负相关；ｐ１６阳性组和 ｃｙｃｌｉｎＤ１阴性组复发率明显低于 ｐ１６阴性组和ｃｙｃｌｉｎＤ１阳性组；ｐ１６阳性组和 ｃｐｃｌｉｎＤ１阴性组 ３年存活率明显高于 ｐ１６阴性组和 ｃｙｃｌｉｎＤ１阳性组。结论ｐ１６、ｃｙｃｌｉｎＤ１蛋白检测可作为膀胱ＴＣＣ辅助诊断及预后判断的参考指标。     

细胞周期素D1的表达与肺癌临床生物学特性的关系研究

目的：研究细胞周期素Ｄ１（Ｃｙｃｌｉｎ Ｄ１）在肺癌中的表达及其与肺癌临床生物学特性的关系。方法：采用免疫斑点和免疫组化法对４６例肺癌患进行Ｃｙｃｌｉｎ Ｄ１检测。结果：Ｃｙｃｌｉｎ Ｄ１在肺癌中的表达高于正常肺组织，且与肺癌的分化和转移密切相关，与吸烟也有一定关系。结论：Ｃｙｃｌｉｎ Ｄ１的过在肺癌发生发展过程中可能起到重要作用。     

p16,Rb,CDK4和cyclinD1在非小细胞肺癌中的表达及其作用

探讨细胞周期调控因子在非小细胞肺癌组织中的表达及作用。方法应用ＬＳＡＢ免疫组化的方法对１２３例原发性非小细胞肺癌进行检测。结果５１．２％的肺癌出现ｃｙｃｌｉｎＤ１的过表达，７７．２％的肿瘤组织表达，ＣＤＫ４，并与肿瘤的分化程度呈反比。有淋巴结转移的肺癌其ｃｙｃｌｉｎＤ１的ＣＤＫ４的阳性率分别为８７．３％和６８．４％。无淋巴结转移的肺癌阳性率分别为１２．６％和３１．５％。两者相比差异有显著性（Ｐ〉／     

非霍奇金淋巴瘤CyclinD1和p34^cdc2蛋白的检测

为了研究非霍奇金淋巴瘤（ＮＨＬｓ）中细胞周期调节因子ＣｙｃｌｉｎＤ１和ｐ３４＾ｃｄｃ２蛋白表达与肿瘤分化程度和免疫分型的关系,对４０例ＮＨＬｓ进行ＣｙｃｌｉｎＤ１和ｐ３４＾ｃｄｃ２蛋白免疫组化（ＳＰ法）染色。在４０例ＮＨＬｓ中,有１９例（４７．５％）ＣｙｃｌｉｎＤ１阳性表达２３例（５７．５％（ｐ３４＾ｃｄｃ２阳性表达。１０例淋巴结良性病变中６例生发中心细胞ＣｙｃｌｉｎＤ１和ｐ３４＾ｃｄｃ２弱 是必     

膀胱移行细胞癌组织中cyclin D1和CDK4的表达及其与临床病？…

目的 研究膀胱移行细胞组织中ｃｙｃｌｉｎＤ１和ＣＤＫ４的表达及其与临床病理变化的关系。方法 采用免疫组化方法对正常膀胱和６９例膀胱移行细胞癌组织中ｃｙｃｌｉｎＤ１和ＣＤＫ４的表达进行观察。结果 膀胱移行细胞癌组织中ｃｙｃｌｉｎＤ１的表达高于正常膀胱组织（Ｐ〈０．０５）。ｃｙｃｌｉｎＤ１表达阳性者的肿瘤细胞分化较差，术后易复发，生存时间较短；而ＣＤＫ４的阳性表达仅与患者术后复发有关（Ｐ〈０．０５），     

细胞周期素A的表达与非小细胞肺癌增殖及预后的关系

目的：探讨非小细胞肺癌中 ｃｙｃｌｉｎ Ａ的表达与细胞增殖活性及预后的关系。方法：采用免疫组化法检测 ｃｙｃｌｉｎ Ａ在６０例非小细胞肺癌中的表达,采用流式细胞术分析ＤＮＡ含量。结果：在非小细胞肺癌中 ｃｙｃｌｉｎ Ａ的阳性率为４８．３％（２９／６０）,ｃｙｃｌｉｎ Ａ阳性者的Ｓ期细胞比例［（１４．４±３．９）％］明显高于阴性者［（９．４±３．５）％］,ｃｙｃｌｉｎ Ａ的表达与患者预后有关。结论： ｃｙｃｌｉｎ Ａ的表达与肿瘤细胞增殖活性增高密切相关,是判断非小细胞肺癌患者预后的一个可参考指标。     

细胞周期蛋白cyclin D1、CDK4在食管癌中的表达及其意义

目的：获得食管癌发生过程中调节Ｇ１细胞周期各种因子的作用。方法：采用抗ｃｙｃｌｉｎＤ１和ＣＤＫ４的单克隆抗体对１０例下沉食管和５０例食管鳞状上皮癌标本进行免疫组织化学染色。结果：ｃｙｃｌｉｎＤ１和ＣＤＫ４在正常食管上皮呈现较低水平的表达,在食管鳞状上皮癌中则过表达。２７／５０食管鳞状上皮癌ｙｃｙｃｌｉｎＤ１染色阳性,其中８例强阳性,１２例只表达ＣＤＫ４,１１例只表达ｃｙｃｌｉｎＤ１,１４例既表达ｃ     

细胞周期蛋白D1在非小细胞肺癌中表达的临床意义

目的 探讨非小细胞肺癌（ＮＳＣＬＣ）中细胞周期蛋白Ｄ１（ＣｙｃｌｉｎＤ１）的表达及其临床意义。方法 用鼠抗人ＣｙｃｌｉｎＤ１单克隆抗体（ＤＣＳ／６）对８９例石蜡包埋的原发性ＮＳＣＣＬ组织进行免疫组化染色，并与２０例肺炎性病变比较。结果 ＣｙｃｌｉｎＤ２在肺鳞癌、腺癌、大细胞癌中都有较高的表达，其阳性率分别为６０．５％、６１．０％、４０．０％；而在肺炎性病变中，在肺鳞癌、腺癌中，肿块直径≥３ｃｍ、有     

非霍奇金淋巴瘤中Cyclin D1和p34~(cdc2)蛋白的检测

为了研究非霍奇金淋巴瘤（ＮＨＬｓ）中细胞周期调节因子ＣｙｃｌｉｎＤ１ 和ｐ３４ｃｄｃ２ 蛋白表达与肿瘤分化程度和免疫分型的关系,对４０ 例ＮＨＬｓ 进行ＣｙｃｌｉｎＤ１ 和ｐ３４ｃｄｃ２ 蛋白免疫组化（ＳＰ法）染色。在４０ 例ＮＨＬｓ 中,有１９ 例（４７．５ ％）ＣｙｃｌｉｎＤ１ 阳性表达,２３ 例（５７．５ ％）ｐ３４ｃｄｃ２ 阳性表达。１０ 例淋巴结良性病变中６ 例生发中心细胞ＣｙｃｌｉｎＤ１ 和ｐ３４ｃｄｃ２ 弱阳性表达。低分化ＮＨＬｓ 的ＣｙｃｌｉｎＤ１ 和ｐ３４ｃｄｃ２ 阳性率明显高于高分化ＮＨＬｓ（Ｐ＜ ０．０５）,而同免疫分型无关（ Ｐ＞０ ．０５） 。２ 个细胞周期调节因子的表达具有高度一致性（Ｐ＜０ ．０５）。提示２ 个细胞周期调节因子参与ＮＨＬｓ 的发生发展过程,其阳性表达率及表达强度同ＮＨＬｓ 恶性程度有密切关系,而同免疫分型无明显联系。ＣｙｃｌｉｎＤ１ 和ｐ３４ｃｄｃ２ 蛋白在部分ＮＨＬｓ 中共同起作用,使Ｇ１ →Ｓ期和Ｇ２ →Ｍ 期２ 个细胞检查点控制减弱。     

p53、Cyclin D1及PCNA在非小细胞肺癌的表达

目的 研究非小细胞肺癌（NSCLC）中p53、Cyclin D1蛋白表达及与细胞增殖的关系。方法 应用免疫组织化学技术（SP法）检测74例NSCLC中p53、Cyclin D1蛋白和增殖细胞抗原（PCNA）的表达情况。结果 p53蛋白、CyclinD1蛋白在NSCLC中阳性表达率分别为55．41％和37．84％,均明显高于正常肺组织（P1＝0．0031,P2＝0．0429）。 p53蛋白表达与淋巴结转移有密切关系（P＝0．0222）。p53蛋白、CyclinD1蛋白表达分别与PCNA指数有密切关系（P1＝0．001,P2＝0．0009）。p53蛋白与CyclinD1蛋白表达之间未见明显关系（P＞0．05）。结论 p53蛋白和CyclinD1蛋白近表达参与了NSCLC的发生发展,有促进细胞增殖的作用。p53的诊断和评价NSCLC预后的重要参数。     

Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers.

Cyclin D1 is a cell cycle regulator essential for G1 phase progression and is frequently overexpressed in several human tumour types as a consequence of gene amplification or chromosomal rearrangements. We analysed the expression of cyclin D1 in 75 patients with transitional cell carcinoma (TCC) to investigate the possible relationship between its expression and clinical outcome as well as histopathological findings using the immunohistochemical method. We observed strong staining (++, > 50% positive cells) for cyclin D1 in 19 cases (25.3%) and weak staining (+, 5-50% positive cells) in 19 cases (25.3%). Overexpression of cyclin D1 was not associated with tumour invasion. No significant association was found between overexpression of cyclin D1 and tumour grade (P > 0.05). We assessed the differences of disease-free interval in superficial tumours and actuarial survival probability in invasive tumours according to the status of cyclin D1 expression. Tumours with (++) staining for cyclin D1 recurred much more rapidly than (-) and/or (+) staining tumours (P < 0.01 for - vs ++; P < 0.05 for + vs ++). However, overexpression of cyclin D1 was not associated with a shortened overall survival of patients with invasive tumours (P < 0.1). These results suggest that genetic alteration of cyclin D1 appears to be an early event in the tumorigenesis of bladder TCC and is associated with early recurrence in superficial tumours.     

Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.

Cyclin D1 is one of the G1 cyclins that control cell cycle progression by allowing G1 to S transition. Overexpression of cyclin D1 has been postulated to play an important role in the development of human cancers. We have investigated the correlation between cyclin D1 overexpression and known clinicopathological factors and also its prognostic implication on resected non-small-cell lung cancer (NSCLC) patients. Formalin-fixed and paraffin-embedded tumour tissues resected from 69 NSCLC patients between stages I and IIIa were immunohistochemically examined to detect altered cyclin D1 expression. Twenty-four cases (34.8%) revealed positive immunoreactivity for cyclin D1. Cyclin D1 overexpression is significantly higher in patients with lymph node metastasis (50.0% vs 14.4%, P = 0.002) and with advanced pathological stages (I, 10%; II, 53.8%; IIIa, 41.7%, P = 0.048; stage I vs II, IIIa, P = 0.006). Twenty-four patients with cyclin D1-positive immunoreactivity revealed a significantly shorter overall survival than the patients with negativity (24.0 +/- 3.9 months vs 50.1 +/- 6.4 months, P = 0.0299). Among 33 patients between stages I and II, nine patients with cyclin D1-positive immunoreactivity had a much shorter overall survival (29.7 +/- 6.1 months vs 74.6 +/- 8.6 months, P = 0.0066). These results suggest that cyclin D1 overexpression is involved in tumorigenesis of NSCLCs from early stage and could be a predictive molecular marker for poor prognosis in resectable NSCLC patients, which may help us to choose proper therapeutic modalities after resection of the tumor.     

The expressions and significance of α-, β-catenins and cyclin D1 in breast cancers

Objective  To study the relationship between expressions of α-, β-catenins and cyclin D1 and the occurrence, infiltration and metastasis of breast cancer. Methods  High sensitive S-P immunohistochemical method was used to detect the protein expressions of α-, β-catenins and cyclin D1 in the 60 cases of breast cancer tissues. Results  Abnormal immunoreactivities of α-and β-catenins were observed in 37 (61.7%) and 42 (70%) cases of breast cancer tissues, respectively. There were 28 cases (46.7%) who showed cyclin D1 overexpression. The abnormal expression rates of α-and β-catenins in infiltrating lobular carcinoma (ILC) were significantly higher than those in infiltrating ductal carcinoma (IDC) (P < 0.05), but they had no relations to the extent of differentiation and lymphatic metastasis of breast cancer (P > 0.05). The overexpression rate of cyclin D1 was correlated with tumor stage and lymphatic metastasis of breast cancer (P < 0.05), but not with histological type and the extent of differentiation (P > 0.05). Cyclin D1 overexpression was observed in 57.1% (24/42) of these cases that showed abnormal staining of β-catenin, but only observed in 22.2% (4/18) of these cases with normal membranous staining of β-catenin. There was a significantly positive correlation between the abnormal expression of β-catenin and overexpression of cyclin D1 (r _s = 0.321, P < 0.05). Conclusion  The abnormal expression of β-catenin may play an important role in the genesis of breast cancer by triggering cyclin D1 overexpression in breast cancer. The abnormal expressions of α-and β-catenins are not a key factor in malignant cell metastasis in breast cancer, but may also involve in the progress.     

非小细胞肺癌中DEC1与cyclin D1的表达及其临床意义

目的:分析differentiated embryonic chondrocyte expressed gene 1（DEC1）和cyclin D1在非小细胞肺癌组织中的表达和相关性及其与临床病理因素间的关系。方法:采用免疫组化方法检测DEC1和cyclin D1在134例非小细胞肺癌中的表达情况。结果:在134例非小细胞肺癌中,DEC1细胞核的平均阳性表达率为（27.6±9.26）%,明显低于DEC1癌旁正常组织中细胞核的平均阳性表达率（84.3±19.70）%。DEC1表达下调或缺失与肺癌的低分化（P=0.008）以及高p-TNM分期(P=0.001)相关。而cyclin D1表达与肺癌低分化（P=0.003）,肿瘤大小（P=0.038）,高p-TNM分期（P=0.017）及淋巴结转移（P=0.037）正相关。并且DEC1在肺癌中的细胞质表达与cyclin D1的表达显著负相关（P=0.003）。结论:DEC1表达与cyclin D1表达负相关,并与肿瘤分化,肺癌患者高p-TNM分期负相关。     

Cyclin D1 overexpression as a prognostic factor in patients with esophageal carcinoma.

BACKGROUND AND OBJECTIVES: Cyclin D1 is known to play important roles in the G1/S check-point of the cell cycle. We investigated the correlation between cyclin D1 overexpression and clinical characteristics to clarify its prognostic significance in patients with esophageal cancer. METHODS: From 1991 to 1998, cyclin D1 was investigated in esophageal cancers from 86 patients who underwent esophagectomy. Overexpression of cyclin D1 was demonstrated using an immunohistochemical method. RESULTS: Overexpression of cyclin D1 was found in 23 (26.7%) of 86 cases. Overexpression of cyclin D1 correlated with lymph node metastasis (P = 0.0083) and lymphatic vessel invasion (P = 0.018). Cyclin D1 overexpression may indicate resistance to chemotherapy. The patients with cyclin D1 overexpression had a significantly lower survival rate than those without overexpression (P = 0.013). The multivariate analysis revealed cyclin D1 overexpression to be an important prognostic factor in patients with esophageal cancer. CONCLUSIONS: Immunohistochemical examination of cyclin D1 expression may provide important prognostic information in univariate and multivariate analysis and may be necessary for determining therapeutic strategies for esophageal cancer.     

The Relationships between cyclin D1 Expression and Prognosis of Non-small Cell Lung Cancer

Background and objective cyclin D1 is a member of the cyclin family, and it has been proven that it plaied an important role in tumorigenesis, invasion and metastasis. We performed a retrospective study on the cyclin D1 expression in non-small cell lung cancer (NSCLC) according to the clinical characteristics. Methods One hundred fifteen postsurgical NSCLC patients were investigated. Immunohistochemistry was used to evaluate the cyclin D1 expression. Results Overall survival was significantly lower in patients with cyclin D1-high expression of tumors than those with cyclin D1 low expression of tumors (χ2=5.132, P=0.023). In early stage patients (stage I, II), the overall survival was significantly lower in patients with cyclin D1-high expression of tumors than those with cyclin D1-low expression of tumors (χ2=6.863, P=0.009). cyclin D1 status (hazard ratio=0.630; P=0.035), differentiation (hazard ratio=0.399; P<0.001), and pTNM (hazard ratio=1.576; P<0.001) to be independent prognostic factors for NSCLC patients. Specifically, the cyclin D1 status (hazard ratio=0.188; P=0.008) was a significant prognostic factor for patients with stage I NSCLCs. Conclusion cyclin D1 expression is an independent prognosis factor for postoperative patient in stage I, II NSCLCs.     

乳腺癌组织中E-cadherin、β-catenin及cyclin D1表达的相关性研究

背景与目的上皮性钙粘素(E-cadherin)通过连接素(catenins)与细胞骨架相连介导细胞同质粘附反应,β-catenin除与E-cadherin结合介导细胞粘附反应外,还作为Wnt信号转导通路的重要成分与肿瘤发生密切相关。本研究通过检测乳腺癌组织中E-cadherin、β-catenin及cyclinD1的表达,探讨E-cadherin、β-catenin在乳腺癌发生、发展中的意义。方法采用免疫组织化学SP法检测60例乳腺癌组织中E-cadherin、β-catenin、cyclinD1的表达。结果乳腺癌组织中有29例(48.3%)E-cadherin、18例(30.0%)β-catenin正常表达,28例(46.7%)cyclinD1过度表达。E-cadherin正常表达病例中,31.0%(9/29)的病例呈现cyclinD1过度表达,而E-cadherin异常表达病例中,61.3%(19/31)的病例呈现cyclinD1过度表达,E-cadherin异常表达与cyclinD1的过度表达有显著的正相关性(rs=0.303,P<0.05)。有42例癌组织表现出β-catenin的异常表达,其中57.1%(24/42)的病例出现cyclinD1的过度表达,而β-catenin正常膜表达病例中,22.2%(4/18)的病例呈现cyclinD1的过度表达。β-catenin的异常表达与cyclinD1的过度表达有显著的正相关性(rs=0.321,P<0.05)。结论E-cadherin和β-catenin的异常表达可能通过促使或激活cyclinD1的过度表达导致乳腺癌的发生和发展。     

ezrin和E-cadherin在非小细胞肺癌中的表达及意义

背景与目的 有研究表明埃兹蛋白(ezrin)可与上皮钙黏素(E-cadherin)相互作用,参与肿瘤细胞的转移过程.本研究的目的是利用组织芯片技术探讨ezrin和E-cadherin在非小细胞肺癌(NSCLC)组织和淋巴结转移灶中的表达及其意义.方法 应用免疫组织化学LSAB法检测25例良性病变肺组织、287例NSCLC原发灶及120例淋巴结转移灶中ezrin和E-cadherin蛋白的表达.结果 NSCLC原发灶及淋巴结转移灶中ezrin过度表达率分别为57.8%(166/287)和83.3%(100/120),E-cadherin异常表达率分别为82.6%(237/287)和98.3%(118/120),差异均有统计学意义(P=0.000).ezrin过度表达率与病理分级(P=0.005)、转移(P=0.032)有密切关系.E-cadherin异常表达率与病理分级(P=0.024)、转移(P=0.015)、TNM分期(P=0.037)有密切关系.ezrin与E-cadherin表达呈负相关(P=0.029).COX多因素分析显示病理分级、转移、TNM分期、ezrin表达和E-cadherin表达是影响肺癌患者预后的危险因素(P＜0.05).结论 ezrin和E-cadherin可能与肺癌的转移有关;二者有可能作为NSCLC患者临床预后判断的指标.